Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma
Chiara Chiavelli, Malvina Prapa, Giulia Rovesti, Marco Silingardi, Giovanni Neri, Giuseppe Pugliese, Lucia Trudu, Massimiliano Dall’Ora, Giulia Golinelli, Giulia Grisendi, Jonathan Vinet, Marco Bestagno, Carlotta Spano, Vito Roberto Papapietro, Roberta Depenni, Katia Di Emidio, Anna Pasetto, Daniela Nascimento Silva, Alberto Feletti, Silvia Berlucchi, Corrado Iaccarino, Giacomo Pavesi, Massimo Dominici
Abstract
Glioblastoma (GBM) remains a deadly tumor. Treatment with chemo-radiotherapy and corticosteroids is known to impair the functionality of lymphocytes, potentially compromising the development of autologous CAR T cell therapies. We here generated pre-clinical investigations of autologous anti-GD2 CAR T cells tested against 2D and 3D models of GBM primary cells. We detected a robust antitumor effect, highlighting the feasibility of developing an autologous anti-GD2 CAR T cell-based therapy for GBM patients.